Hubei Goto Biopharm Co 300966.SZ · CNY

Its shares trade on Shenzhen under the ticker 300966.SZ. It has been listed since 9 April 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥606.2m and a net loss of CN¥73.4m. At that date it held total assets of CN¥2.85bn and shareholders' equity of CN¥826.2m.

Hubei Goto Biopharm Co., Ltd. engages in the research, development, production, and sale of steroidal drug raw materials. The company is headquartered in Xiangfan, Hubei. The company went IPO on 2021-04-09. The firm's main products are starting materials and intermediates required for the production of steroid drugs. The starting materials refer to the products obtained from the conversion of plant sterols through biological fermentation technology. These products are important raw materials for downstream pharmaceutical intermediates and active pharmaceutical ingredient manufacturers and belong to the upstream products in the steroid drug industry chain. The firm's intermediate products mainly include sex hormone intermediates, progesterone intermediates, corticosteroid intermediates and other products.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Zubin XiChairman of the Board, General Manager, Director of R&D, since 2018CN¥868,000
• Mr. Xiangdong LiuChief Financial Officer, Director, since 2018CN¥399,800
• Ms. Wenjing ChenDeputy General Manager, Secretary of the BoardCN¥649,800
• Mr. Minglei LiDeputy General Manager, Director, since 2008CN¥677,800
• Mr. Xueming WangDirectorCN¥289,700
• Mr. Deliang HeIndependent Director
• Mr. Ziwu LongIndependent Director
• Mr. Fei QiIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.